Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.55 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.55 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.55 |
| ▸ | POLA1 | P09884 | 2/20 | 0.54 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.45 |
| ▸ | ALB | P02768 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.45 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.40 |
| ▸ | POLG | P54098 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL20769295 | 1.00 | PDE3A (0.73) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL232223 | 0.95 | PDE3A (0.80) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL15316783 | 0.95 | PDE3A (0.80) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL1254191 | 0.91 | PDE3A (0.73) | PDE3APDE4DSLC29A1LMNATHRB | |
| Gemcitabine SCHEMBL350020 | 0.90 | PDE3A (0.91) | PDE3APDE4DSLC29A1LMNATHRB | |
| Gemcitabine SCHEMBL17978348 | 0.90 | PDE3A (0.91) | PDE3APDE4DSLC29A1LMNATHRB | |
| Gemcitabine SCHEMBL285130 | 0.90 | PDE3A (0.91) | PDE3APDE4DSLC29A1LMNATHRB | |
| Gemcitabine SCHEMBL348218 | 0.90 | PDE3A (0.91) | PDE3APDE4DSLC29A1LMNATHRB | |
| Gemcitabine SCHEMBL28334969 | 0.89 | PDE3A (0.89) | PDE3APDE4DSLC29A1LMNATHRB | |
| Phosphoric Acid SCHEMBL20769284 | 0.88 | PDE3A (0.68) | PDE3APDE4DSLC29A1LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11041151-B2 | RNA array compositions and methods | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2021-06-22 | — | — | US | disclosed |
| US-10167474-B2 | Cell-specific internalizing RNA aptamers against human CCR5 and uses therefore | CITY OF HOPE (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180112211-A1 | RNA Array Compositions and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-04-26 | — | — | US | disclosed |
| US-20180080026-A1 | CELL-SPECIFIC INTERNALIZING RNA APTAMERS AGAINST HUMAN CCR5 AND USES THEREFORE | THE SCRIPPS RESEARCH INSTITUTE | 2018-03-22 | — | — | US | disclosed |
| US-9605266-B2 | Cell-specific internalizing RNA aptamers against human CCR5 and uses therefore | CITY OF HOPE (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160193202-A1 | THERAPEUTIC TREATMENT FOR DRUG POISONING AND ADDICTION | ADISPELL, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160053265-A1 | CELL-SPECIFIC INTERNALIZING RNA APTAMERS AGAINST HUMAN CCR5 AND USES THEREFORE | THE SCRIPPS RESEARCH INSTITUTE | 2016-02-25 | — | — | US | disclosed |
| WO-2015023664-A2 | THERAPEUTIC TREATMENT FOR DRUG POISONING AND ADDICTION | ADISPELL, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| US-20140235505-A1 | RNA ARRAY COMPOSITIONS AND METHODS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2014011768-A1 | ANTI-ANXIETY TREATMENT | ADISPELL, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20050096290-A1 | 5'-and 3'-capped aptamers and uses therefor | (OSI) EYETECH, INC. | 2005-05-05 | — | — | US | disclosed |
| WO-2005014814-A2 | 5’-AND 3’-CAPPED APTAMERS AND USES THEREFOR | (OSI) EYETECH, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-6849610-B1 | Polynucleotide ligands as anti-viral agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-01 | — | — | US | disclosed |
| EP-0724647-A4 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | GILEAD SCIENCES INC (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2001038341-A1 | POLYNUCLEOTIDE LIGANDS AS ANTI-VIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-05-31 | — | — | WO | disclosed |
| US-6184364-B1 | DEHYDRATING URIDINE TO FORM 2,2'-ANHYDROURIDINE, CONVERTING TO UNPROTECTED 2'-AZIDO-2'-DEOXYURIDINE, IODINATING TO FORM 5-IODO-2'-AZIDO, 2'-DEOXYURIDINE, THEN REDUCING TO 5-IODO, 2'-AMINO-2'-DEOXYURIDINE; SELEX LIGANDS | NEXSTAR PHARMACEUTICALS, INC. | 2001-02-06 | — | — | US | disclosed |
| US-5958691-A | DETECTION OF NUCLEIC ACID LIGANDS WITH MODIFIED NUCLEOTIDE TO TARGET GROUPS, SINGLE STRAND NUCLEIC ACIDS AND PARTITIONING THE NUCLEIC ACIDS, AMPLIFICATION | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5660985-A | CONTACTING MIXTURE OF MODIFIED SINGLE-STRANDED NUCLEIC ACIDS WITH TARGET MOLECULE, PARTITIONING THOSE WITH INCREASED AFFINITY, AMPLIFYING TO IDENTIFY LIGANDS OF TARGET MOLECULE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-08-26 | — | — | US | disclosed |
| EP-0724647-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NeXstar Pharmaceuticals, Inc. (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995007364-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NEXSTAR PHARMACEUTICALS, INC. (US) | 1995-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193202-A1 | THERAPEUTIC TREATMENT FOR DRUG POISONING AND ADDICTION | CHRNG, CHRM3, CHRNA5 | PDE3A 2346/4885PDE4D 2893/4885SLC29A1 922/4885 |
| US-20050096290-A1 | 5'-and 3'-capped aptamers and uses therefor | FLT4, TEK, FLT1 | PDE3A 302/4885PDE4D 170/4885SLC29A1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.